Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Research in context

Summary: Background: The Bruton's tyrosine kinase inhibitor ibrutinib and the proteasome inhibitor bortezomib have single-agent activity, non-overlapping toxicities, and regulatory approval in mantle cell lymphoma (MCL). In vitro, their combination provides synergistic cytotoxicity. In this investi...

Description complète

Détails bibliographiques

Auteurs principaux:	Urban Novak, Martin Fehr, Sämi Schär, Martin Dreyling, Christian Schmidt, Enrico Derenzini, Thilo Zander, Georg Hess, Ulrich Mey, Simone Ferrero, Nicolas Mach, Carola Boccomini, Sebastian Böttcher, Michèle Voegeli, Anne Cairoli, Vanesa-Sindi Ivanova, Thomas Menter, Stefan Dirnhofer, Bernhard Scheibe, Sandra Gadient, Katrin Eckhardt, Emanuele Zucca, Christoph Driessen, Christoph Renner
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2023-10-01
Collection:	EClinicalMedicine
Sujets:	Mantle cell lymphoma High risk biology Ibrutinib Bortezomib
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S258953702300398X
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!